# A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

> **NCT06690281** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Gastrointestinal Carcinoma
- Pancreatic Cancer
- Hepatocellular Cancer
- Cholangiocarcinoma
- Duodenal Cancer
- Colorectal Cancer
- Small Bowel Cancer
- Metastatic Cancers

## Interventions

- **BIOLOGICAL:** KRAS TCR-Transduced PBL
- **DRUG:** Aldesleukin
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06690281
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-09-09
- **Primary completion:** 2025-09-09
- **Final completion:** 2025-09-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI left NIH.
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06690281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06690281, "A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06690281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*